Suppr超能文献

健康信息技术干预措施与艾滋病毒护理参与以及在美国公共资助环境中实现病毒抑制的成本效益分析。

Health information technology interventions and engagement in HIV care and achievement of viral suppression in publicly funded settings in the US: A cost-effectiveness analysis.

机构信息

Institute for Global Health Sciences, Department of Epidemiology and Biostatistics, University of California, San Francisco, California, United States of America.

Center for AIDS Prevention Studies, University of California, San Francisco, California, United States of America.

出版信息

PLoS Med. 2021 Apr 7;18(4):e1003389. doi: 10.1371/journal.pmed.1003389. eCollection 2021 Apr.

Abstract

BACKGROUND

The US National HIV/AIDS Strategy (NHAS) emphasizes the use of technology to facilitate coordination of comprehensive care for people with HIV. We examined cost-effectiveness from the health system perspective of 6 health information technology (HIT) interventions implemented during 2008 to 2012 in a Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program demonstration project.

METHODS/FINDINGS: HIT interventions were implemented at 6 sites: Bronx, New York; Durham, North Carolina; Long Beach, California; New Orleans, Louisiana; New York, New York (2 sites); and Paterson, New Jersey. These interventions included: (1) use of HIV surveillance data to identify out-of-care individuals; (2) extension of access to electronic health records (EHRs) to support service providers; (3) use of electronic laboratory ordering and prescribing; and (4) development of a patient portal. We employed standard microcosting techniques to estimate costs (in 2018 US dollars) associated with intervention implementation. Data from a sample of electronic patient records from each demonstration site were analyzed to compare prescription of antiretroviral therapy (ART), CD4 cell counts, and suppression of viral load, before and after implementation of interventions. Markov models were used to estimate additional healthcare costs and quality-adjusted life-years saved as a result of each intervention. Overall, demonstration site interventions cost $3,913,313 (range = $287,682 to $998,201) among 3,110 individuals (range = 258 to 1,181) over 3 years. Changes in the proportion of patients prescribed ART ranged from a decrease from 87.0% to 72.7% at Site 4 to an increase from 74.6% to 94.2% at Site 6; changes in the proportion of patients with 0 to 200 CD4 cells/mm3 ranged from a decrease from 20.2% to 11.0% in Site 6 to an increase from 16.7% to 30.2% in Site 2; and changes in the proportion of patients with undetectable viral load ranged from a decrease from 84.6% to 46.0% in Site 1 to an increase from 67.0% to 69.9% in Site 5. Four of the 6 interventions-including use of HIV surveillance data to identify out-of-care individuals, use of electronic laboratory ordering and prescribing, and development of a patient portal-were not only cost-effective but also cost saving ($6.87 to $14.91 saved per dollar invested). In contrast, the 2 interventions that extended access to EHRs to support service providers were not effective and, therefore, not cost-effective. Most interventions remained either cost-saving or not cost-effective under all sensitivity analysis scenarios. The intervention that used HIV surveillance data to identify out-of-care individuals was no longer cost-saving when the effect of HIV on an individual's health status was reduced and when the natural progression of HIV was increased. The results of this study are limited in that we did not have contemporaneous controls for each intervention; thus, we are only able to assess sites against themselves at baseline and not against standard of care during the same time period.

CONCLUSIONS

These results provide additional support for the use of HIT as a tool to enhance rapid and effective treatment of HIV to achieve sustained viral suppression. HIT has the potential to increase utilization of services, improve health outcomes, and reduce subsequent transmission of HIV.

摘要

背景

美国国家艾滋病战略(NHAS)强调利用技术来促进艾滋病毒感染者综合护理的协调。我们从卫生系统的角度评估了 2008 年至 2012 年在瑞安怀特艾滋病毒/艾滋病计划(RWHAP)特别项目国家意义(SPNS)计划示范项目中实施的 6 项健康信息技术(HIT)干预措施的成本效益。

方法/发现:在 6 个地点实施了 HIT 干预措施:纽约州布朗克斯;北卡罗来纳州达勒姆;加利福尼亚州长滩;路易斯安那州新奥尔良;纽约州纽约市(2 个地点);以及新泽西州帕特森。这些干预措施包括:(1)使用艾滋病毒监测数据识别失访者;(2)扩大电子健康记录(EHR)的获取范围,以支持服务提供者;(3)使用电子实验室订单和处方;和(4)开发患者门户。我们采用标准微观成本核算技术来估算干预措施实施相关的成本(2018 年美元)。从每个示范站点的电子患者记录中抽取样本进行分析,以比较干预措施实施前后抗逆转录病毒治疗(ART)、CD4 细胞计数和病毒载量的处方情况。马尔可夫模型用于估计由于每个干预措施而导致的额外医疗保健成本和质量调整生命年的节省。总体而言,在 3 年期间,3110 名患者(范围为 258 至 1181 名)的示范地点干预措施成本为 3913313 美元(范围为 287682 美元至 998201 美元)。患者接受 ART 处方的比例发生了变化,从第 4 地点的 87.0%降至 72.7%,到第 6 地点的 74.6%升至 94.2%;0 至 200 CD4 细胞/mm3 的患者比例从第 6 地点的 20.2%降至 11.0%,到第 2 地点的 16.7%升至 30.2%;无法检测到病毒载量的患者比例从第 1 地点的 84.6%降至 46.0%,到第 5 地点的 67.0%升至 69.9%。在 6 项干预措施中,有 4 项——包括使用艾滋病毒监测数据识别失访者、使用电子实验室订单和处方、开发患者门户——不仅具有成本效益,而且还具有成本节约效果(每投资 1 美元可节省 6.87 至 14.91 美元)。相比之下,扩大 EHR 访问权限以支持服务提供者的 2 项干预措施没有效果,因此没有成本效益。在所有敏感性分析情景下,大多数干预措施仍然要么具有成本节约效果,要么没有成本效益。当 HIV 对个体健康状况的影响降低,HIV 自然进展增加时,使用 HIV 监测数据识别失访者的干预措施不再具有成本节约效果。本研究的结果是有限的,因为我们没有为每项干预措施提供同期对照;因此,我们只能根据基线情况评估各站点,而不能在同一时期评估标准护理情况。

结论

这些结果为利用 HIT 作为增强艾滋病毒快速有效治疗以实现持续病毒抑制的工具提供了更多支持。HIT 有可能增加服务的利用,改善健康结果,并减少随后的艾滋病毒传播。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6eb/8059802/e6edd764b434/pmed.1003389.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验